Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E39'
- Development stage
- Unknown
- Lead developer
- Galena Biopharma
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
E39' (also known as GALE-302) is an attenuated peptide vaccine derived from the folate binding protein (FBP), designed for use in cancer immunotherapy. It is a modified version of the E39 peptide, which targets FBP—a protein highly overexpressed in ovarian, endometrial, and breast cancers. The vaccine is administered with granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate cytotoxic T lymphocytes to recognize and destroy FBP-expressing cancer cells. Clinical trials have evaluated its safety and efficacy in preventing recurrence of gynecological cancers, particularly ovarian and endometrial adenocarcinomas[5][7].
- Other names
- GALE-302GALE302GALE 302
02
Targets
T-cell receptor specific for Folate Binding Protein (FBP)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on E39'.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E39'.